Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR012330)
Formula
SVG example
Unclear
Reactant DFdCMP Product DFdCDP
Reactant Info Product Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001121 Gemcitabine Gemcitabine Monophosphate Other reaction - Phosphorylation Gemcitabine [1], [2]
MR012329 DFdC DFdCMP Unclear - Unclear CO-101 [3]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001119 Gemcitabine Monophosphate 2',2'-difluorodeoxyuridine monophosphate Oxidation - Deamination Gemcitabine [4]
MR012332 DFdCMP DFdUMP Unclear - Unclear CO-101 [3]
Other MR(s) Related to The Product of This MR
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001120 Gemcitabine diphosphate Gemcitabine triphosphate Other reaction - Phosphorylation Gemcitabine [5], [6], [7]
MR012331 DFdCDP DFdCTP Unclear - Unclear CO-101 [3]
References
1 Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective Cancer Chemother Pharmacol. 2016 Jul;78(1):1-12. doi: 10.1007/s00280-016-3003-0.
2 Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer Drugs. 1997 Sep;54(3):447-72. doi: 10.2165/00003495-199754030-00009.
3 Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
4 LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study J Pharm Biomed Anal. 2021 May 10;198:114025. doi: 10.1016/j.jpba.2021.114025.
5 Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides Br J Clin Pharmacol. 2018 Jun;84(6):1279-1289. doi: 10.1111/bcp.13557.
6 A metal-dependent conformational change provides a structural basis for the inhibition of CTP synthase by gemcitabine-5'-triphosphate. Protein Sci. 2023 Jun;32(6):e4648. doi: 10.1002/pro.4648.
7 Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review. Eur J Clin Pharmacol. 2022 Jul;78(7):1087-1093. doi: 10.1007/s00228-022-03324-z.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.